Cortexyme Appoints June Bray to its Board of Directors – Yahoo Finance


SOUTH SAN FRANCISCO, Calif., June 13, 2022–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors.
"We are very pleased to welcome a seasoned pharmaceutical and global regulatory expert of June Bray’s caliber to our Board of Directors," said David Lamond, chairperson of Cortexyme’s Board of Directors. "With more than four decades of pharmaceutical industry experience, we look forward to her valuable contribution and perspective across multiple therapeutic areas."
"I am excited to join Cortexyme’s Board of Directors as the company works to efficiently and effectively advance its current clinical stage therapeutics, in addition to expanding its development pipeline in strategic ways," said June Bray. "I look forward to supporting the new leadership team as they work to establish a clear roadmap for driving the company’s clinical stage and discovery pipeline, and in the evaluation of new business development opportunities."
To the Cortexyme Board of Directors, Ms. Bray brings more than forty years of extensive U.S. and global regulatory experience in the healthcare industry and a proven track record of successful regulatory interactions with health authorities which have led to the approval of 32 NDAs in the U.S. and multiple international approvals. She most recently served as Senior Vice President, Global Regulatory Affairs and Medical Writing at Allergan, where she was responsible for regulatory strategies on development projects and lifecycle management in all therapeutic areas, including psychiatry and neurology. During her tenure, she led numerous NDA approvals, including Namenda XR®, Namzaric®, Vraylar®, and Ubrelvy®. Previously, Ms. Bray served as Vice President, Regulatory Affairs at Organon (now Merck), where she led regulatory activities for development and marketed products, including the NDA for Saprhis® (asenapine) for the treatment of schizophrenia and bipolar disorder. Earlier in her career, Ms. Bray held numerous roles of increasing responsibility over a 25-year period at Berlex Laboratories, Inc. (now Bayer HealthCare Pharmaceuticals). She began her pharmaceutical career in sterile manufacturing at Hoechst-Roussel Pharmaceuticals (now Sanofi-Aventis). Ms. Bray holds a B.S. in Pharmacy from the University of Rhode Island and an M.B.A in Pharmaceutical Marketing from Fairleigh Dickinson University.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company focused on rare and degenerative diseases. The company’s innovative pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005110/en/
Contacts
Stacy Roughan
Cortexyme, Inc.
Vice President, Corporate Communications & Investor Relations
ir@cortexyme.com
Related Quotes
Dr. Owen Garrick is aiming to mend a broken system with more equitable enrollment in clinical trials, as he shares in Hearst’s “Future Rising.”
Patient partners are at the heart of the four research projects selected for the 2nd edition of the "Priorité patient" competition organized by Oncopole – the cancer division of the Fonds de recherche du Québec – Santé (FRQS). This competition provides financial support for research projects aimed at improving the care and services for people living with cancer in Quebec.
ADC Therapeutics SA (NYSE: ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301) in relapsed or refractory Hodgkin lymphoma. Cami demonstrated a 70.1% overall response rate (ORR), with a 33.3% complete response (CR) rate. From a safety perspective, eight of 117 patients developed Guillain-Barré syndrome (GBS)/polyradiculopathy. HC Wainwright says that after considering the highly advanced nature of these patients, the respon
Cooper Standard (NYSE: CPS) today announced the promotion of Amy Kulikowski to vice president, chief accounting officer effective July 11, 2022. She replaces Becky McCabe who is departing the Compa…
Bluebird Bio stock was flying high Monday after an advisory committee of the Food and Drug Administration recommended two of the biotech’s experimental gene therapies. Shares of Bluebird Bio (ticker: BLUE) surged 28.7%, to $4.80, on Monday. The stock was on track for its largest percent gain in eight years, according to Dow Jones Market Data.
The S&P 500 fell more than 20% below its all-time high on Monday.
The indexes continue to deteriorate ahead of this week’s Fed decision on interest rates. Energy stocks lead the downside.
Buffett swapped out Wells Fargo and Goldman Sachs for a beaten-down bank.
The tech sector might look like a losing investment given the recent performance of many of its stocks. The Nasdaq is deep into bear territory, and the growth-oriented ARK Innovation ETF has lost about three-fourths of its value.
Investors are running out of superlatives to describe how ugly the S&P 500 crash is. But 11 major stocks are now trading for less than $4.
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the…
Bitcoin prices are moving to their lowest levels since 2020. Economist Adam Schiff, one of the biggest critics of bitcoin and cryptocurrencies, predicts that the most popular digital currency will drop at least as low as $20,000. Bitcoin alone represents a bit more than 45% of the crypto market, according to data firm CoinGecko.
The World Trade Organization is meeting this week to consider adopting an agreement that would make it easier to produce COVID-19 vaccines and treatments by waiving patent enforcement during health emergencies.
The week has started off rough for cryptocurrencies, with bitcoin tumbling and troubles for some cryptocurrency platforms as U.S. inflation rattles investors.
FedEx Corp. stock soared 13% Tuesday to put it on track for the biggest one-day gain in about 29 years, after the company raised its quarterly dividend by 53% as part of a new agreement with activist investor D.E. Shaw.
DocuSign (NASDAQ: DOCU) was one of them — its suite of digital tools transformed from a luxury to a necessity for many organizations. As in-person business continues to pick back up, DocuSign is facing an abrupt slowdown in growth and a stock price that has declined 80% from its all-time high. DocuSign is best known for pioneering digital signature technology, but that one-dimensional business model is long in the past thanks to the company’s aggressive investment in innovation.
Edward Thorp is an investing and mathematical legend — from spotting Bernie Madoff’s fraud as well as identifying Warren Buffett’s investing acumen early, to coming up with blackjack game theory. It was a sobering if measured reply — the inductee to the Blackjack Hall of Fame said he was reading about what’s going on with American society. “You could have the choices I just described — a devolution, evolution or revolution,” Thorp said.
Yahoo Finance’s Jared Blikre breaks down how markets opened on Tuesday.
The crypto crash comes amid broad selloffs of risk assets. Meanwhile, Celsius paused all withdrawals from customers, which worries investors.
Inflation data dominated the market news at the end of last week, and rightly so. The May print, of 8.6% annualized gains in the consumer price index, marked a sharp reversal from the modest decline seen in April, and a new ‘highest level in 40 years’ data point. It reignited worries that the rosy projections – of a transient inflation, or of lower rates by early next year – are unlikely to reach fruition. Even though unemployment is low and wages are up, the declines in real earnings and the GD

source


Leave a Reply

Your email address will not be published.